MARKET

PHIO

PHIO

Phio Pharmaceuticals Corp
NASDAQ
1.900
+0.090
+4.97%
Pre Market: 1.860 -0.04 -2.11% 06:07 05/14 EDT
OPEN
1.750
PREV CLOSE
1.810
HIGH
2.090
LOW
1.750
VOLUME
29
TURNOVER
--
52 WEEK HIGH
9.79
52 WEEK LOW
0.9657
MARKET CAP
9.08M
P/E (TTM)
-0.2093
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PHIO last week (0505-0509)?
Weekly Report · 2d ago
Phio Pharmaceuticals Reports Positive Phase 1b Trial Results
TipRanks · 6d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 6d ago
Phio Pharma Announces Pathology Results In Third Dose Cohort in INTASYL PH-762 Skin Cancer Clinical Trial
Benzinga · 6d ago
Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial
Newsfile · 6d ago
Weekly Report: what happened at PHIO last week (0428-0502)?
Weekly Report · 05/05 10:08
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Newsfile · 05/01 11:45
Weekly Report: what happened at PHIO last week (0421-0425)?
Weekly Report · 04/28 10:13
More
About PHIO
More
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
Recently
Symbol
Price
%Change

Webull offers Phio Pharmaceuticals Corp stock information, including NASDAQ: PHIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PHIO stock methods without spending real money on the virtual paper trading platform.